---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-21-010321"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2021-09-23T23:59:59+00:00"
generated_at: "2026-06-29T01:42:38.712899+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# GT Biopharma files 8-K regarding ESMO 2021 presentation; no financial results disclosed

## Summary
- Dr. Jeffrey Miller presented on GT Biopharma's drug candidates at ESMO Congress 2021.
- Updated corporate presentation posted to website as of Sept 20, 2021.
- No specific clinical data or financial figures included in this filing.

## SEC filing metadata
- accession: 0001654954-21-010321
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2021-09-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000165495421010321/0001654954-21-010321-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000165495421010321/gtbp_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-21-010321
- JSON: https://secwatch.observer/filing/0001654954-21-010321.json
- Plain text: https://secwatch.observer/filing/0001654954-21-010321.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.